We are pleased to announce that Mindray has recently reached an equity transfer agreement with Hangzhou Optcla Medical Instrument Co., Ltd. (“Optcla”) to acquire a controlling stake in the company.
Under the agreement, Optcla will give Mindray access to its rigid endoscope and related surgical devices as well as its R&D, manufacture, sales and services capabilities. This acquisition will further supplement and extend Mindray’s existing total solutions for hospital operation rooms, cater to the market trend of increasing demand for minimally invasive operations and digitalized operations, as well as bringing new growth for Mindray.
Optcla will be operated independently under its former management team after the acquisition. Mindray has no plans to change Optcla’s employee base. Mindray will also honor all of Optcla’s contracts as agreed upon prior to the acquisition and maintain Optcla’s current policies on sale and after-sale service.
Mindray will use its strong platforms in sales, manufacture, R&D, quality assurance and human resources to support Optcla’s future development. Mindray aims to work diligently with Optcla to help the company become a leader in the promising rigid endoscope and related surgical devices business in China.
We believe the collaboration between Mindray and Optcla will bring many synergies to both parties. Together, we will provide better products and services to our customers, and broader development opportunities to our employees. Mindray will also help strengthen Optcla’s position in the marketplace.
About Optcla:
Optcla is a leading high-tech enterprise headquartered in Tonglu, Hangzhou, China, mainly engaged in R&D, design, manufacturing and sale of rigid endoscope and related minimally invasive surgical devices.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
May 09, 2012
